LumiraDx Investor Presentation Deck
TB Molecular Program Demonstrates Feasibility to
Develop Swab Based POC Test
Key Targets and Workflow
Tongue swab sample
Results in 20 minutes
Access to testing for HIV+ and pediatric
populations, currently underserved
Performance Feasibility
Copy
number
(cp/rxn)
11
5.6
1.3
0.6
lumiraDx™
No of
positives
8/8
8/8
33/38
3/8
% positivity
100
100
87
33
Value Proposition
POC TB test has opportunity to increase patients linked to care
Number of patients at each step of cascade
5,000,000
4,500,000
4,000,000
3,500,000
3,000,000
2,500,000
2,000,000
1,500,000
1,000,000
500,000
2,840,000
100%
Individuals with
incident TB
1,938,027
Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
68%
1,629,906
Accessed TB
tests
57%
1,417,838
50%
1,221,764
43%
Diagnosed with
TB
Registered in
treatment
TB Care Cascade in Indian Public Health System
B
Treatment
success
1,049,237
I
37%
Recurrence-free
survivalView entire presentation